Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Newly Diagnosed MGMT Promotor Unmethylated Glioblastoma
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
- 主要终点
- OVER SURVIVAL
研究概览
简要总结
Temozolomide provided significant and clinically meaningful benefit in MGMT gene promoter methylation glioblastoma. However, in unmethylated patients, the effect of Temozolomide is limited. The aim of this study is to compare the effect of Etoposide plus Cisplatin and Temozolomide in patients with MGMT gene promoter unmethylation glioblastoma.
详细描述
60 Patients with glioblastoma were recruited for this study based on the following eligibility criteria: Age between 18 and 70, performance status of 0-1 (Eastern Cooperative Oncology Group performance status), histologically confirmed MGMT gene promoter unmethylation glioblastoma, no cerebrospinal fluid and distant metastatic disease. All patients had adequate hematologic, hepatic, and renal function. Patients younger than 18 years; patients with a prior (i.e. within 5 years) or synchronous malignancy, other than non-melanoma skin cancer; and those with significant comorbidities were excluded.
60 patients were randomly divided into two groups and compared the difference of efficacy between the two groups
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age between 18 and 70,
- •performance status of 0-1 (Eastern Cooperative Oncology Group performance status),
- •histologically confirmed MGMT gene promoter unmethylation glioblastoma
- •no cerebrospinal fluid and distant metastatic disease.
- •adequate hematologic, hepatic, and renal function
排除标准
- •younger than 18 years;
- •with a prior (i.e. within 5 years) or synchronous malignancy, other than non-melanoma skin cancer; and those with significant comorbidities
研究组 & 干预措施
Etoposide Plus Cisplatin group
Etoposide 100mg/m2 d1-5 Cisplatin 20mg/mCisplatin d1-5
干预措施: Etoposide Plus Cisplatin (Drug)
结局指标
主要结局
OVER SURVIVAL
时间窗: 2 YEARS
The length of time from the date of diagnosis to death from cancer
次要结局
- PFS(1 year)